We break viruses
We make oral drugs to treat and prevent viral infections - like COVID-19.
Key people at Pardes Biosciences.
Pardes Biosciences was founded in 2020 by Uri Lopatin (Founder/CEO).
Pardes Biosciences was founded in 2020 by Uri Lopatin (Founder/CEO).
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies to treat and prevent COVID-19 and other coronavirus infections. Its lead product candidate, PBI-0451, is an oral protease inhibitor designed to block the coronavirus main protease essential for viral replication. Pardes aims to address pandemic-scale public health challenges by applying modern reversible-covalent chemistry to discover novel oral drugs, improving patient access and outcomes globally[1][2][7].
Founded in early 2020 amid the COVID-19 pandemic, Pardes Biosciences was created with the mission to solve pandemic-sized problems starting with COVID-19. The company was co-founded by a team including CEO Uri A. Lopatin, M.D., leveraging expertise in drug discovery and clinical development. The idea emerged from the urgent need for effective oral antivirals against SARS-CoV-2. Early traction included advancing PBI-0451 into Phase I clinical trials by late 2021 and going public via a SPAC merger with FS Development Corp. II, backed by investors like RA Capital and Gilead Sciences[1][2].
Pardes Biosciences rides the global trend of accelerating antiviral drug development in response to the COVID-19 pandemic and future pandemic preparedness. The timing is critical as oral antivirals offer a scalable, accessible treatment option complementing vaccines and monoclonal antibodies. Market forces favor companies that can rapidly develop broad-spectrum antivirals targeting conserved viral proteins, addressing emerging variants and potential future coronavirus outbreaks. Pardes contributes to the biopharma ecosystem by advancing novel chemistry platforms and focusing on patient-centric oral therapies, influencing antiviral drug discovery paradigms[1][2][4].
Looking ahead, Pardes Biosciences aims to complete clinical development of PBI-0451 and potentially expand its antiviral pipeline using its reversible covalent chemistry platform. Trends shaping its journey include increasing demand for oral antivirals, evolving coronavirus variants, and heightened global focus on pandemic preparedness. As the company matures, its influence may grow by delivering accessible antiviral treatments and pioneering chemistry approaches that could extend beyond COVID-19 to other viral diseases. Pardes is positioned to be a key player in the next generation of antiviral therapeutics, continuing its mission to "break viruses" and improve global health outcomes[1][2][7].
Key people at Pardes Biosciences.
